No Prescription |
 |
 | ||
|
Cabgolin Dostinex |
|
| ||
No Prescription » Prescription Drugs 3 » Cabgolin Dostinex Category:Dopamine agonist antihyperprolactinemic Cabergoline (ca-BER-goe-leen) is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems fertility problems in men and women and pituitary prolactinomas (tumors of the pituitary gland).It works by stopping the brain from making and releasing the prolactin hormone from the pituitary. Cabergoline use is usually stopped when prolactin levels are normal for 6 months. It may be given again if symptoms of too much prolactin occur again.Cabergoline is in a group of drugs called dopamine receptor antagonists. It works by reducing the amount of prolactin (a hormone) that is released from the pituitary gland. Cabergoline is used to treat a hormone imbalance in which there is too much prolactin in the blood (also called hyperprolactinemia).Treating disorders associated with high levels of the hormone prolactin either due to tumors in the pituitary gland or to unknown causes. It may also be used for other conditions as determined by your doctor.Cabergoline is a dopamine receptor agonist. It works by blocking prolactin secretion from the pituitary gland. Buy Cabgolin Dostinex and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About Cabgolin Dostinex: Product Type: Prescription Drugs 3 Cabgolin ( Dostinex Generic Cabergoline ) Cabgolin (Dostinex Generic Cabergoline) Dostinex Generic Cabergoline 0.25mg 4 Boxes ( 16 Tabs ) 12 Boxes ( 48 Tabs ) 0.50mg 12 Boxes ( 48 Tabs ) 4 Boxes ( 16 Tabs ) Dostinex Generic Cabergoline Cabgolin
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
